← Back to Vaccine Database

SII B.1.617.2 + Matrix-M1 adjuvant, a monovalent SII SARS-CoV-2 B.1.617.2 (Delta) variant vaccine

Protein based vaccine · VDDBV0698

Target & Classification

SARS-CoV-2SARS-CoV-2
Protein based vaccine
COVID-19
Phase 2

Clinical Development

Phase 1
Phase 2
Phase 3
Approved

Clinical Trials1

NCT IDPhaseDisease / Condition
NCT05029858 Phase 2COVID-19